Urinary Concentrations of the Soluble Adhesion Molecule E-cadherin and Total Protein in Patients with Bladder Cancer

Overview

Journal Br J Cancer

Specialty Oncology

Date 1999 Jul 2

PMID 10390008

Citations 11

Authors

A S Protheroe

R E Banks

M Mzimba

W H Porter

J Southgate

P N Singh

M Bosomworth

P Harnden

P H Smith

P Whelan

P J Selby

Affiliations

Soon will be listed here.

Abstract

Reduced expression of the adhesion molecule E-cadherin has been associated with increased invasiveness and poorer survival in patients with bladder cancer. We have examined soluble E-cadherin (sE-cadherin) and total protein concentrations in urine from patients with bladder cancer (n = 34), non-neoplastic benign urological diseases (n = 14) and healthy controls (n = 21) to determine their diagnostic and prognostic significance. Soluble E-cadherin concentrations of the cancer group were significantly higher (P < 0.001) than those of the controls but the benign group was not significantly different from either the cancer group or the controls. When sE-cadherin concentrations were adjusted for creatinine, similar but more statistically significant results were obtained and the benign group was significantly elevated compared with the controls (P < 0.01). No differences were apparent between the invasive (pT1-4) and non-invasive (pTa) cancers. Urinary total protein concentrations in the cancer group were significantly higher than the controls (P < 0.001) and the benign group (P < 0.05) although no difference was seen between the benign group and patients with non-invasive (pTa) cancer or between the benign group and controls. When expressed as the protein/creatinine index, results were similar but more statistically significant and a significant difference was seen between invasive and non-invasive cancers (P < 0.01). Only the protein/creatinine index correlated significantly with stage of the tumour (P < 0.01). It is concluded that urinary sE-cadherin measurements are of no greater value than urinary total protein.

Citing Articles

Pentapartite fractionation of particles in oral fluids by differential centrifugation.

Hiraga C, Yamamoto S, Hashimoto S, Kasahara M, Minamisawa T, Matsumura S Sci Rep. 2021; 11(1):3326.

PMID: 33558596 PMC: 7870959. DOI: 10.1038/s41598-021-82451-6.

CD82 Suppresses ADAM17-Dependent E-Cadherin Cleavage and Cell Migration in Prostate Cancer.

Ma Z, Gao Y, Liu W, Zheng L, Jin B, Duan B Dis Markers. 2020; 2020:8899924.

PMID: 33204367 PMC: 7654213. DOI: 10.1155/2020/8899924.

Urine E-cadherin: A Marker for Early Detection of Kidney Injury in Diabetic Patients.

Koziolek M, Mueller G, Dihazi G, Jung K, Altubar C, Wallbach M J Clin Med. 2020; 9(3).

PMID: 32121033 PMC: 7141221. DOI: 10.3390/jcm9030639.

Levels of soluble E-cadherin in breast, gastric, and colorectal cancers.

Repetto O, de Paoli P, De Re V, Canzonieri V, Cannizzaro R Biomed Res Int. 2014; 2014:408047.

PMID: 25535613 PMC: 4182303. DOI: 10.1155/2014/408047.

Cleavage of transmembrane junction proteins and their role in regulating epithelial homeostasis.

Nava P, Kamekura R, Nusrat A Tissue Barriers. 2014; 1(2):e24783.

PMID: 24665393 PMC: 3879235. DOI: 10.4161/tisb.24783.

References

Lipponen P, Eskelinen M . Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer. J Cancer Res Clin Oncol. 1995; 121(5):303-8. DOI: 10.1007/BF01209598. View

Banks R, Porter W, Whelan P, Smith P, Selby P . Soluble forms of the adhesion molecule E-cadherin in urine. J Clin Pathol. 1995; 48(2):179-80. PMC: 502407. DOI: 10.1136/jcp.48.2.179. View

Reading J, Hall R, Parmar M . The application of a prognostic factor analysis for Ta.T1 bladder cancer in routine urological practice. Br J Urol. 1995; 75(5):604-7. DOI: 10.1111/j.1464-410x.1995.tb07417.x. View

Becker K, Hofler H . Frequent somatic allelic inactivation of the E-cadherin gene in gastric carcinomas. J Natl Cancer Inst. 1995; 87(14):1082-4. DOI: 10.1093/jnci/87.14.1082. View

Yoshiura K, Kanai Y, Ochiai A, Shimoyama Y, Sugimura T, Hirohashi S . Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci U S A. 1995; 92(16):7416-9. PMC: 41350. DOI: 10.1073/pnas.92.16.7416. View

Ross J, del Rosario A, Figge H, Sheehan C, Fisher H, Bui H . E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder. Hum Pathol. 1995; 26(9):940-4. DOI: 10.1016/0046-8177(95)90081-0. View

DHallewin M, Baert L . Initial evaluation of the bladder tumor antigen test in superficial bladder cancer. J Urol. 1996; 155(2):475-6. View

Syrigos K, Krausz T, Waxman J, Pandha H, Rowlinson-Busza G, VERNE J . E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissues: correlation with histopathological grade, tumour stage and survival. Int J Cancer. 1995; 64(6):367-70. DOI: 10.1002/ijc.2910640603. View

Mao L, Schoenberg M, Scicchitano M, Erozan Y, Merlo A, Schwab D . Molecular detection of primary bladder cancer by microsatellite analysis. Science. 1996; 271(5249):659-62. DOI: 10.1126/science.271.5249.659. View

10.

Griffiths T, Brotherick I, Bishop R, White M, McKenna D, Horne C . Cell adhesion molecules in bladder cancer: soluble serum E-cadherin correlates with predictors of recurrence. Br J Cancer. 1996; 74(4):579-84. PMC: 2074678. DOI: 10.1038/bjc.1996.404. View

11.

Yoshida K, Sugino T, Tahara H, Woodman A, Bolodeoku J, Nargund V . Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer. 1997; 79(2):362-9. DOI: 10.1002/(sici)1097-0142(19970115)79:2<362::aid-cncr20>3.0.co;2-y. View

12.

Tsuji M, Kojima K, Murakami Y, Kanayama H, Kagawa S . Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens. Br J Urol. 1997; 79(3):367-72. DOI: 10.1046/j.1464-410x.1997.02710.x. View

13.

Caliskan M, Turkeri L, Mansuroglu B, Toktas G, Aksoy B, Unluer E . Nuclear accumulation of mutant p53 protein: a possible predictor of failure of intravesical therapy in bladder cancer. Br J Urol. 1997; 79(3):373-7. DOI: 10.1046/j.1464-410x.1997.06911.x. View

14.

Kinoshita H, Ogawa O, Kakehi Y, Mishina M, Mitsumori K, Itoh N . Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J Natl Cancer Inst. 1997; 89(10):724-30. DOI: 10.1093/jnci/89.10.724. View

15.

Steiner G, Schoenberg M, Linn J, Mao L, Sidransky D . Detection of bladder cancer recurrence by microsatellite analysis of urine. Nat Med. 1997; 3(6):621-4. DOI: 10.1038/nm0697-621. View

16.

Leyh H, Hall R, MAZEMAN E, Blumenstein B . Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder. Urology. 1997; 50(1):49-53. DOI: 10.1016/S0090-4295(97)00206-9. View

17.

Gohji K, Fujimoto N, Ohkawa J, Fujii A, Nakajima M . Imbalance between serum matrix metalloproteinase-2 and its inhibitor as a predictor of recurrence of urothelial cancer. Br J Cancer. 1998; 77(4):650-5. PMC: 2149919. DOI: 10.1038/bjc.1998.104. View

18.

Kanayama H, Yokota K, Kurokawa Y, Murakami Y, Nishitani M, Kagawa S . Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer. 1998; 82(7):1359-66. View

19.

Hiraguri S, Godfrey T, Nakamura H, Graff J, Collins C, Shayesteh L . Mechanisms of inactivation of E-cadherin in breast cancer cell lines. Cancer Res. 1998; 58(9):1972-7. View

20.

Jones L, Levin A, Fudenberg H . Glomerular antigen complexes associated with transitional cell carcinoma. Surg Gynecol Obstet. 1975; 140(6):896-8. View